October 23, 2016 4:42 AM ET


Company Overview of Igenica, Inc.

Company Overview

Igenica, Inc., a biotherapeutic company, engages in the discovery and development of antibodies and antibody-drug conjugates for the treatment of cancer. The company focuses on the development of immunotherapies, functional antibodies directed to the tumor, and antibody-drug conjugates for the treatment of cancer. It provides IGN523, a humanized monoclonal antibody for the treatment of various hematologic and solid tumors; IGN786, an antibody-drug conjugate; and IGN381, an immune checkpoint target that plays a complimentary role in the tumor micro-environment to other known immune checkpoints. Igenica, Inc. has a strategic oncology research agreement with MedImmune. The company was founded i...

863A Mitten Road

Suite 100B2

Burlingame, CA 94010

United States

Founded in 2008





Key Executives for Igenica, Inc.

Executive Chairman
Age: 64
Co-Founder and Vice President of Research
Co-Founder, Chairman of Scientific Advisory Board and Director
Chief Financial Officer
Chief Scientific Officer
Compensation as of Fiscal Year 2016.

Igenica, Inc. Key Developments

Igenica, Inc. Presents at BBC BD Boston, Mar-09-2016 10:30 AM

Igenica, Inc. Presents at BBC BD Boston, Mar-09-2016 10:30 AM. Venue: The Westin Copley Place, 10 Huntington Avenue, Boston, MA 02116, United States. Speakers: John K. Celebi, Chief Business Officer.

Igenica Biotherapeutics Signs Oncology Research Deal with MedImmune

Igenica Biotherapeutics has signed an oncology research agreement with AstraZeneca's subsidiary MedImmune. The companies will assess the potential of antibody-drug conjugates (ADCs) targeting Surface Antigen in Leukemia (SAIL). SAIL is a novel cell surface protein with high prevalence of expression in several hematologic malignancies and solid tumors. Preclinical data have supported the selective targeting of tumors expressing SAIL with ADCs. Igenica will provide its anti-SAIL antibodies, including IGN786, and its SNAP ADC drug linker, while MedImmune will contribute its anti-tumor payload. Both the companies will then jointly investigate the resulting novel ADC in preclinical studies. MedImmune will have an option to an exclusive worldwide license to anti-SAIL antibodies and antibody-drug conjugates that arise from the partnership. Igenica will have an exclusive option fee. If MedImmune exercises its option, the company will also receive an upfront license fee, clinical, regulatory and commercialization milestones, and royalties on net sales. The development and commercialization costs will be funded by MedImmune under a license agreement.

Igenica Biotherapeutics, Inc. Presents at BIO-Europe 2015, Nov-02-2015

Igenica Biotherapeutics, Inc. Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Igenica, Inc., please visit www.igenica.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.